638 related articles for article (PubMed ID: 15668962)
1. Microglial activation and dopamine terminal loss in early Parkinson's disease.
Ouchi Y; Yoshikawa E; Sekine Y; Futatsubashi M; Kanno T; Ogusu T; Torizuka T
Ann Neurol; 2005 Feb; 57(2):168-75. PubMed ID: 15668962
[TBL] [Abstract][Full Text] [Related]
2. Neuroinflammation in the living brain of Parkinson's disease.
Ouchi Y; Yagi S; Yokokura M; Sakamoto M
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S200-4. PubMed ID: 20082990
[TBL] [Abstract][Full Text] [Related]
3. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography.
Ouchi Y; Yoshikawa E; Okada H; Futatsubashi M; Sekine Y; Iyo M; Sakamoto M
Ann Neurol; 1999 May; 45(5):601-10. PubMed ID: 10319882
[TBL] [Abstract][Full Text] [Related]
4. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Sakamoto M
Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989
[TBL] [Abstract][Full Text] [Related]
5. Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET.
Yagi S; Yoshikawa E; Futatsubashi M; Yokokura M; Yoshihara Y; Torizuka T; Ouchi Y
J Nucl Med; 2010 Aug; 51(8):1250-7. PubMed ID: 20660377
[TBL] [Abstract][Full Text] [Related]
6. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT.
Kim SE; Choi JY; Choe YS; Choi Y; Lee WY
J Nucl Med; 2003 Jun; 44(6):870-6. PubMed ID: 12791812
[TBL] [Abstract][Full Text] [Related]
7. Age and severity of nigrostriatal damage at onset of Parkinson's disease.
De La Fuente-Fernández R; Lim AS; Sossi V; Adam MJ; Ruth TJ; Calne DB; Stoessl AJ; Lee CS
Synapse; 2003 Feb; 47(2):152-8. PubMed ID: 12454953
[TBL] [Abstract][Full Text] [Related]
8. Function of sigma1 receptors in Parkinson's disease.
Mishina M; Ishiwata K; Ishii K; Kitamura S; Kimura Y; Kawamura K; Oda K; Sasaki T; Sakayori O; Hamamoto M; Kobayashi S; Katayama Y
Acta Neurol Scand; 2005 Aug; 112(2):103-7. PubMed ID: 16008536
[TBL] [Abstract][Full Text] [Related]
9. [[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy.
Berding G; Brücke T; Odin P; Brooks DJ; Kolbe H; Gielow P; Harke H; Knoop BO; Dengler R; Knapp WH
Nuklearmedizin; 2003 Feb; 42(1):31-8. PubMed ID: 12601452
[TBL] [Abstract][Full Text] [Related]
10. Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.
Prunier C; Payoux P; Guilloteau D; Chalon S; Giraudeau B; Majorel C; Tafani M; Bezard E; Esquerré JP; Baulieu JL
J Nucl Med; 2003 May; 44(5):663-70. PubMed ID: 12732666
[TBL] [Abstract][Full Text] [Related]
11. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO
Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035
[TBL] [Abstract][Full Text] [Related]
12. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease.
Ribeiro MJ; Vidailhet M; Loc'h C; Dupel C; Nguyen JP; Ponchant M; Dollé F; Peschanski M; Hantraye P; Cesaro P; Samson Y; Remy P
Arch Neurol; 2002 Apr; 59(4):580-6. PubMed ID: 11939892
[TBL] [Abstract][Full Text] [Related]
13. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.
Nurmi E; Ruottinen HM; Kaasinen V; Bergman J; Haaparanta M; Solin O; Rinne JO
Ann Neurol; 2000 Jun; 47(6):804-8. PubMed ID: 10852547
[TBL] [Abstract][Full Text] [Related]
14. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
Lee CS; Samii A; Sossi V; Ruth TJ; Schulzer M; Holden JE; Wudel J; Pal PK; de la Fuente-Fernandez R; Calne DB; Stoessl AJ
Ann Neurol; 2000 Apr; 47(4):493-503. PubMed ID: 10762161
[TBL] [Abstract][Full Text] [Related]
15. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease.
Hwang WJ; Yao WJ; Wey SP; Ting G
J Nucl Med; 2004 Feb; 45(2):207-13. PubMed ID: 14960637
[TBL] [Abstract][Full Text] [Related]
16. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study.
Sossi V; de la Fuente-Fernández R; Schulzer M; Troiano AR; Ruth TJ; Stoessl AJ
Ann Neurol; 2007 Nov; 62(5):468-74. PubMed ID: 17886297
[TBL] [Abstract][Full Text] [Related]
17. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging.
Cicchetti F; Brownell AL; Williams K; Chen YI; Livni E; Isacson O
Eur J Neurosci; 2002 Mar; 15(6):991-8. PubMed ID: 11918659
[TBL] [Abstract][Full Text] [Related]
18. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease.
Frost JJ; Rosier AJ; Reich SG; Smith JS; Ehlers MD; Snyder SH; Ravert HT; Dannals RF
Ann Neurol; 1993 Sep; 34(3):423-31. PubMed ID: 8363363
[TBL] [Abstract][Full Text] [Related]
20. Presynaptic dopaminergic function in patients with restless legs syndrome: are there common features with early Parkinson's disease?
Linke R; Eisensehr I; Wetter TC; Gildehaus FJ; Pöpperl G; Trenkwalder C; Noachtar S; Tatsch K
Mov Disord; 2004 Oct; 19(10):1158-62. PubMed ID: 15390076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
